BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251120T190000
DTEND;TZID=Africa/Nairobi:20251122T203000
DTSTAMP:20260526T023247
CREATED:20251118T071137Z
LAST-MODIFIED:20251223T172117Z
UID:40558-1763665200-1763843400@kesho-kenya.org
SUMMARY:Management of Non-Small Cell Lung Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nBRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer \nDate: 20th November 2025Time: 7 PM – 8:30 PM EAT \n(CPD ACCREDITED) \n\nModerator\nDr. Muhindi WanjuguPhysician and Chest Specialist\, The Nairobi Hospital\, Doctors Plaza\, Nairobi \n\nSpeakers\nDr. Nuruddin JoomaHaemato-Oncologist\, Florida Cancer Specialists & Research Institute\, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer \nDr. Morris MuhingaConsultant Cardiothoracic Surgeon\, The Nairobi HospitalShift in Surgical Paradigm \nSummary: \nLung Cancer: Contemporary Clinical Management and Emerging Evidence \nPresentations by Dr Nuruddin Jooma and Dr Morris Muhinga \nThe sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management\, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early\, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification\, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing. \nKey clinical principles discussed included optimal diagnostic pathways incorporating imaging\, histopathology and immunohistochemistry\, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection\, avoid inappropriate use of immunotherapy and improve survival outcomes. \nCurrent standards of care were reviewed across disease stages\, including surgical management in early-stage disease\, the expanding role of neoadjuvant and adjuvant systemic therapies\, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms. \nBoth presentations reinforced the need for timely diagnosis\, biomarker-driven treatment decisions and coordinated multidisciplinary care\, while acknowledging ongoing challenges related to access\, treatment sequencing and long-term disease control. \nKey takeaway: Optimal lung cancer outcomes depend on precise staging\, comprehensive molecular testing and evidence-based\, multidisciplinary treatment across the disease continuum.
URL:https://kesho-kenya.org/event/management-of-non-small-cell-lung-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-17-at-10.34.44-PM-e1763449878610.jpeg
END:VEVENT
END:VCALENDAR